XOMA (NASDAQ:XOMA) Earns “Buy” Rating from HC Wainwright

XOMA (NASDAQ:XOMA)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a research report issued to clients and investors on Thursday, Benzinga reports. They presently have a $74.00 target price on the biotechnology company’s stock. HC Wainwright’s price target suggests a potential upside of 191.22% from the stock’s current price.

XOMA Price Performance

XOMA stock opened at $25.41 on Thursday. The stock has a 50-day moving average price of $24.86 and a two-hundred day moving average price of $20.38. The stock has a market cap of $295.77 million, a PE ratio of -6.29 and a beta of 0.58. The company has a current ratio of 8.68, a quick ratio of 8.68 and a debt-to-equity ratio of 1.34. XOMA has a 1 year low of $13.48 and a 1 year high of $27.00.

XOMA (NASDAQ:XOMA) last released its earnings results on Friday, March 8th. The biotechnology company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.13). The firm had revenue of $1.83 million for the quarter, compared to the consensus estimate of $1.01 million. XOMA had a negative return on equity of 25.17% and a negative net margin of 886.91%. Equities analysts forecast that XOMA will post -1.73 EPS for the current fiscal year.

Hedge Funds Weigh In On XOMA

An institutional investor recently raised its position in XOMA stock. Stonepine Capital Management LLC lifted its holdings in shares of XOMA Co. (NASDAQ:XOMA) by 25.0% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 436,602 shares of the biotechnology company’s stock after buying an additional 87,203 shares during the period. XOMA comprises 2.0% of Stonepine Capital Management LLC’s holdings, making the stock its 12th largest position. Stonepine Capital Management LLC owned approximately 3.80% of XOMA worth $6,152,000 as of its most recent SEC filing. 95.92% of the stock is currently owned by institutional investors.

XOMA Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.